Variable | Categories | Risk of change | Reasons for changing DMARD | |
---|---|---|---|---|
Risk of adverse drug reaction | Risk of lack of efficacy | |||
Female gender | Y/N | 1.11 (0.69 - 1.80) | 1.52 (0.81 – 2.85) | 1.20 (0.71 – 2.03) |
Age | Quartiles | 0.89 (0.72 - 1.10) | 1.23 (0.94 – 1.60) | 0.69 (0.55 – 0.87) ** |
Ever smoked | Y/N | 1.38 (0.89 - 2.15) | 1.29 (0.59 – 2.78) | 1.35 (0.83 – 2.19) |
DAS28 | EULAR categories | 1.12 (0.78 - 1.62) | 0.95 (0.58 – 1.57) | 1.29 (0.83 – 2.02) |
>4 of 1987 ACR criteria | Y/N | 0.98 (0.59 – 1.65) | 1.04 (0.57 – 1.91) | 1.20 (0.72 – 2.01) |
Extra-articular disease | Y/N | 1.78 (1.00 - 3.16) * | 1.29 (0.59 – 2.78) | 2.27 (1.25 – 4.11) ** |
Co-morbidities | Y/N | 1.02 (0.66 - 1.57) | 1.18 (0.67 – 2.09) | 0.82 (0.51 – 1.32) |
HAQ score | Quartiles | 1.44 (1.12 - 1.86) ** | 1.10 (0.80 – 1.52) | 1.36 (1.03 – 1.81) * |
SF36-bodily pain | Quartiles | 0.93 (0.72 - 1.19) | 1.03 (0.75 – 1.43) | 1.18 (0.90 – 1.55) |
SF36-mental health | Quartiles | 1.44 (1.16 - 1.78) ** | 1.43 (1.08 – 1.89) * | 1.22 (0.97 – 1.52) |
DAS28-P | Quartiles | 1.09 (0.88 - 1.35) | 1.04 (0.79 – 1.37) | 1.10 (0.86 – 1.41) |
SSZ monotherapy | Y/N | 1.09 (0.57 - 2.12) | 1.92 (0.85 – 4.37) | 0.74 (0.35 – 1.54) |
MTX monotherapy | Y/N | 0.56 (0.29 - 1.06) | 0.38 (0.16 – 0.94) * | 0.57 (0.28 – 1.17) |
MTX + SSZ + HCQ | Y/N | 0.30 (0.12 - 0.79) * | 0.33 (0.08 – 1.38) | 0.14 (0.04 – 0.53) ** |